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Background: Malignant pleural effusions continue to be a common problem in patients with metastatic disease,
leading to a significant reduction in quality of life with progressive dyspnea, dry cough, chest pain and reduced
physical activity. This study was conducted to compare the efficacy, safety, and outcome of Talc Powder Pleurodesis
(TPP) with Povidone-iodine Pleurodesis (PIP) through a chest drain as a palliative preventive treatment of recurrent
malignant pleural effusion.
Methods: A total of 39 neoplastic patients with recurrent malignant pleural effusion were enrolled in a prospective
randomized trial. Twenty-one patients received Talc pleurodesis (group A), and eighteen patients (group B) received
Povidone-iodine pleurodesis. The continuous variables were expressed as mean values ± standard deviation (SD)
and compared using the unpaired t-test. The discrete variables were expressed as percentage and compared using
the chi-square test (χ2) test. p-values of less than 0.05 were considered significant.
Results: Our study included 11 males and 28 females, the mean age was (71.0 ± 5.0) years for group A and (70.9 ± 5.1)
years for group B (non-significant). Post-procedure analgesic requirements were recorded in both groups. Four patients
in each group had fever (>38°C) within 48 hours of the procedure. Both groups achieved good symptomatic relief.
There were no in-hospital deaths. The mean post-procedure hospital stay was (4.7 ± 1.2) days for group A and (4.2 ± 1.0)
for group B (non-significant). At follow-up recurrence of significant pleural effusion requiring intervention was noted in
four and five patients in group A and group B, respectively (non-significant difference).
Conclusion: Povidone-iodine pleurodesis can be considered as a good alternative to Talc pleurodesis for recurrent
malignant pleural effusion. The drug is available, cost effective, safe and can be administered through an intercostal
drain and repeated if necessary.
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Pleural effusion is the accumulation of fluid in the
pleural space caused by many conditions, the commonest
of which are; congestive heart failure, pneumonia and
malignancy [1]. Malignant pleural effusions continue to be
a common problem in patients with metastatic disease,
leading to a significant reduction in quality of life with
progressive dyspnea, dry cough, chest pain and reduced
physical activity [2]. The commonest cause of malignant* Correspondence: islammoheb@hotmail.com
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by metastatic breast cancer [3]. The management of
recurrent malignant pleural effusions is palliative, and
should be aiming at improving the quality of life with
minimal complications. The aim of pleurodesis in these
patients is to prevent re-accumulation of the effusion and
thereby of symptoms, and avoid the high cost and physical
and emotional trauma caused by repeated hospitalization
for thoracocentesis [4].
Over the past several years, chemical pleurodesis has
evolved as the most widely accepted treatment method for
these conditions [5]. There are a wide variety of agents
available for pleurodesis, such as tetracycline derivativesl. This is an Open Access article distributed under the terms of the Creative
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bleomycin, mitoxantrone, nitrogen mustard, silver nitrate,
iodopovidone, dry killed Corynebacterium parvum and
OK-432 (obtained from the Su strain of Streptococcus
pyogenes) [6]. Like any other drug, the criteria for selec-
tion of the agent for pleurodesis include its effectiveness,
affordability, availability, ease of administration and safety
profile [7].
Many reports showed talc pleurodesis as the surgical
pleurodesis of choice for recurrent malignant effusion,
with a reported success rate of 90% [8,9]. In Egypt, however,
the use of talc powder has been disapproved and it remains
unavailable in the Egyptian market [4]. Instead, bleomycin,
which is expensive and less effective, is being used.
Povidone–iodine (in a 10% solution), which is primarily
used as a topical antiseptic agent, has recently been shown
to be an inexpensive, easily available, safe, and mostly
effective alternative sclerosing agent in some series [5]. It
also can be infused, with excellent tolerance, through
intercostal drain under local anesthesia and repeated, if
necessary [4].
This study was conducted to compare the efficacy,
safety, and outcome of Talc Powder Pleurodesis (TPP)
with Povidone-iodine Pleurodesis (PIP) through a chest
drain as a palliative preventive treatment of recurrent
malignant pleural effusion.Methods
This study was conducted at the cardiothoracic Surgery
department in Menoufia University Hospitals between
January and November 2013. A total of 39 patients with
malignant pleural effusion were enrolled in a randomized
non-blinded controlled trial. Informed consent was
obtained from each patient and ethical approval for the
study was obtained from the local ethics committee. All
patients diagnosed (clinically and histo-pathologically)
with recurrent malignant pleural effusion were included in
our study. Patients with allergy to iodine and those with
incompletely inflated lung on radiograph were excluded
from the study.
Therapeutic thoracocentesis was performed in all
patients, and the drained pleural fluid amounts were
recorded and sent for physical, biochemical, bacteriological
and cytological evaluation. Patients were then randomized
(using simple randomization with allocation concealment)
into two groups; group A (21 patients), and group B
(18 patients).Technique of pleurodesis
After insertion of wide-pore chest drain (size 28 F - 36 F)
under local anesthesia and allowing for free drainage of
pleural fluid over 6–12 hours, chest radiograph were done
to confirm the drainage of fluid and inflation of the lung.For patients in group A, a dose of 5 grams of sterile,
asbestos-free talc (Steritalc® F2, manufactured by Novatech,
France) in 50 ml of normal saline were instilled through the
chest drain. The chest drain was clamped for 6 hours after
talc instillation.
For patients in group B, 20 ml of 10% Povidone-iodine
(Betadine®, manufactured by Nile Co. for Pharmaceuticals
and Chemical Industries, Cairo, Egypt; licensed by Mundi
Pharma AG, Basel, Switzerland) (Povidone-iodine pH:
4.5 – 5.5) mixed with 10 ml of lidocaine 1% and 30 ml of
normal saline were instilled through the chest drain,
which was clamped for 6 hours as well.
Chest drains were removed when the chest radiograph
confirmed satisfactory lung expansion, and the total
24-hour drainage was less than 100 ml, with no air leak.
Another chest radiograph was done for all patients few
hours post chest drain removal and if satisfactory, patients
were discharge on the same day. Pain was assessed and
scaled using comparative pain scale into; minor pain
(does not interfere with most activities, able to adapt
to pain psychologically and with medication or devices
such as cushions), moderate pain (interferes with many
activities, requires lifestyle changes but patient remains
independent, unable to adapt to pain) and severe pain
(Unable to engage in normal activities, patient is disabled
and unable to function independently). Complications such
as fever, allergic Reactions and empyema were recorded.
Follow-up
All patients were followed-up in the out-patient clinic,
after 2 weeks, 2 months and 6 months. The efficacy of
pleurodesis was defined in three levels of response:
complete (absence of pleural fluid re-accumulation), partial
(residual pleural fluid or re-accumulation, which did not
require further drainage or remained asymptomatic), and
failed (additional pleural procedures were necessary). A
normal chest radiograph or radiological re-accumulation of
pleural fluid without recurrence of dyspnea or the need for
drainage was reported as a success.
Statistical analysis
The continuous variables were expressed as mean values ±
standard deviation (SD) and compared using the unpaired
t-test. The discrete variables were expressed as percentage
and compared using the chi-square test (χ2) test. p-values
of less than 0.05 were considered significant.
Results
A total of 39 patients with malignant pleural effusion
were enrolled during the study period and randomized
into two groups; twenty-one patients in group A, under-
went Talc powder pleurodesis, while eighteen patients in
group B underwent Povidone-iodine pleurodesis through
the intercostal chest drain.
Table 2 Physical, cytological & biochemical analysis of
pleural fluid
Group A Group B p value
N: 21 patients N: 18 patients
Type of effusion 0.493
Exudative* 4 (19.2%) 2 (11.2%)
Transudative* 17 (80.8%) 16 (87.8%)
Character 0.447
Hemorrhagic* 14 (66.7%) 10 (55.6%)
Serosanguinous* 7 (33.3%) 8 (45.4%)
Cytology 0.458
Positive malignant cells* 20 (95.3%) 16 (87.8%)
No malignant cells* 1 (4.7% ) 2 (11.2%)
LDH content (IU/L)^ 220.0 ± 95.5 296.8 ± 75.1 0.209
Total protein (g/L)^ 93.1 ± 55.6 107.0 ± 59.9 0.457
*Number (%).
^mean ± SD.
IU/L: International Unit per Liter.
g/L: gram per Liter.
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Their ages ranged from 65–80 years. There was no
statistically significance difference between both groups
regarding sex, age, height, weight and BMI (Table 1).
There was no statistically significance difference between
both groups regarding pre-pleurodesis medical history
(Table 1). Regarding patients complaints; dyspnea was
present in 38 patients (97.43%), while cough was present in
15 patients (38.46%) and chest pain occurred in 19 patients
(48.71%) with no statistically significance difference
between both groups (Table 1). Also, there was no
statistically significance difference between both groups
regarding history of thoracocentesis (number of thora-
cocentesis per month, amount drained, number of
days before recollection and relief of symptoms). The
mean total pleural fluid drained ± SD was (2.7 ± 0.5 L)
and (2.8 ± 0.4 L) for groups A and B, respectively with
no statistically significant difference.
There was no statistically significance difference between
both groups regarding physical and cytological analysis of
pleural fluid (type of effusion, character and cytology)
(Table 2). There was no statistically significance differenceTable 1 Demographic data and medical history
Group A Group B p value
N: 21 patients N: 18 patients
Sex 0.442
Male* 7 (33.3%) 4 (22.2%)
Female* 14 (66.7%) 14 (77.8%)
Age (years)^ 71.0 ± 5.0 70.9 ± 5.1 0.949
Weight (kg.)^ 77.9 ± 5.3 77.1 ± 5.7 0.652
Height (cm.)^ 174.0 ± 5.5 174.7 ± 5.5 0.687
BMI^ 25.3±1.9 24.8±1.8 0.428
Primary tumor 0.480
Lung* 5 (23.9%) 6 (33.3%)
Breast* 9 (42.9%) 9 (50%)
Unknown* 7 (33.3%) 3 (16.6%)
Symptoms
Dyspnea* 20 (95.3%) 18 (100%) 0.348
Cough* 8 (38.1% ) 7 (38.8%) 0.959
Chest pain* 10 (52.3%) 9 (50%) 0.882
Previous thoracocentesis
Number/month^ 4.7 ± 1.8 4.7 ± 1.5 0.926
Total amount (liters)^ 2.7 ± 0.5 2.8 ± 0.4 0.246
Re-collection after (days)^ 6.1 ± 2.3 6.7 ± 1.5 0.421
Relief of symptoms* 21 (100%) 18 (100%) 1.00
Complete lung inflation* 21 (100%) 16 (87.8%) 0.117
*Number (%).
^mean ± SD.between both groups regarding biochemical analysis of
pleural fluid (LDH content and total protein) (Table 2).
There was no statistically significance difference between
both groups regarding post-pleurodesis success rate and
response to treatment (Table 3). There was no statistically
significance difference between both groups regarding
post-pleurodesis complications (pain, fever, and allergy to
the agent) (Table 3). The most common post-pleurodesis
complication was pain (encountered in 14 patientsTable 3 Post-procedure data





Success rate* 17 (80.9%) 13 (72.2%) 0.519
Response to treatment 0.201
Complete inflation* 15 (71.4%) 12 (66.7%)
Partial inflation* 2 (9.5%) 1 (5.6%)
Failure* 4 (19%) 5 (27.8%)
Complications
Pain (comparative pain scale) 0.291
No pain* 7 (33.3%) 9 (50%)
Minor pain (1-3)* 12 (57.1%) 9 (50%)
Moderate pain (4-6)* 2 (9.5%) 0
Severe pain (7-10)* 0 0
Fever* 4 (19.2%) 4 (22.3%) 0.807
Allergy to agent* 2 (9.6%) 0 0.179
Post-procedure hospital stay(days)^ 4.7 ± 1.2 4.2 ± 1.0 0.172
Recurrence of dyspnea* 4 (19%) 5 (27.7%) 0.519
*Number (%).
^mean ± SD.
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Post-pleurodesis fever was recorded in 4 patients in each
group (Table 3).
During the long-term follow up there was recurrence
of dyspnea in 4 cases with talc powder pleurodesis (19%)
and in 5 cases with Povidone-iodine pleurodesis (27.8%)
with no statistically significant difference between both
groups.
There was no statistically significance difference between
both groups regarding the post-pleurodesis hospital stay
(Table 3). There was one case of mortality recorded in
group A with the cause of death related to the primary
tumor not the pleurodesis. No mortality was recorded in
group B.
Discussion
Recurrent and symptomatic pleural effusions are common
in patients with malignancy. Up to 25% of patients with
lung cancer and 50% of patients with breast cancer will de-
velop a pleural effusion. Overall, mesothelioma, breast and
lung cancer, account for the majority of malignant pleural
effusions. According to underlying disease, many patients
with malignant pleural effusion may live for months or even
years. These patients’ quality of life is therefore of much
importance and the aim of treatment should be beside the
management of the primary disease, is to relieve symptoms,
and to decrease the discomfort of the patient [10]. The
necessity for repeated aspirations to relieve dyspnea is both
physically and psychologically traumatic to the patient and
a burden to the healthcare system. Therefore, the majority
of patients will need a procedure to remove the fluid and
prevent recurrence [11]. Treatment options for malignant
pleural effusions are determined by several factors: symp-
toms and performance status of the patient, the primary
tumor and its response to systemic therapy, and lung
re-expansion following pleural fluid evacuation [12].
Pleurodesis is considered the best palliative therapy for
the treatment of recurrent malignant pleural effusions
[13]. Several techniques and various agents have been
used for this purpose, with variable efficacy and safety
[14]. Talc, tetracycline and bleomycin have been widely
used for pleurodesis. Many studies have shown the effect-
iveness and safety of Povidone-iodine as an agent for
pleurodesis with achieving very good results [3,15].
Our study included 39 cases divided into two groups;
group A had talc pleurodesis and group B had povidone-
iodine pleurodesis. They were 11 males (28.2%) and
28 females (77.8%) with no statistical significant difference
between both groups regarding sex. Our study patients’
ages ranged from 65–80 years. Mean ± SD (71.0 ± 5.0 for
group A and 70.9 ± 5.1 for group B).
Regarding patients’ complaints: the most common
symptom in our study was dyspnea (100% of cases),
followed by cough which occurred in 15 cases, and chestpain that occurred in 19 cases. Occurrence of dyspnea
can be explained as moderate to massive pleural effusion
causing compression on the lung. Also presence of
cough and chest pain in some cases can be explained by
the massive effusion, pleural irritation and chest infec-
tion with no statistical significant difference between
both groups.
Regarding the response to treatment in group A there
was complete response with no fluid re-accumulation in
15 patients (71.4%), and partial response in two patients
(9.5%) with radiologically detected re-accumulation of
minimal to mild amount at 2 months post procedure
but never developed any clinical dyspnea during the
follow-up and failure in 4 cases (19%) with recurrence of
dyspnea and radiologically detected re-accumulation of
moderate to massive pleural effusion. In group B, there
was complete response with no fluid re-accumulation in
12 patients (66.7%), and partial response in one case
(5.6%) who developed re-accumulation of fluid but never
developed any clinical dyspnea, and failure in 5 cases
(27.8%) with recurrence of dyspnea and radiologically
detected re-accumulation of moderate to massive pleural
effusion with no statistically significant difference between
both groups.
In a prospective randomized study, Agarwal R. and
colleagues randomly assigned patients with pleural effusion
or pneumothorax, to receive chemical pleurodesis with
either iodopovidone or cosmetic talc. They studied 38
patients with pleural effusions, who required pleurodesis,
with the common pleural diseases being lung cancer and
pulmonary tuberculosis. They observed complete success
with absence of re-accumulation of fluid on CXR at 30 days
in 16/19 (84.2%) in the iodopovidone group and 15/19
(78.9%) patients in the talc groups [16].
Mohsen et al. studied 44 patients with malignant
pleural effusion secondary to breast cancer, divided into
2 groups using VATS talc pleurodesis in one group and
bedside povidone-iodine in the other group. His study
results match with our study regarding the success
rate between both groups [4]. They reported no fluid
re-accumulation in 19 patients (87%), and partial response
in one patient (4%) and failure in two patients (9%) in the
talc pleurodesis group. In the Povidone-iodine pleurodesis
group, they found that there was complete response with
no fluid re-accumulation in 17 patients (85%) at the early
post-procedure follow-up, and failure response in three
patients (15%) with no statistically significant difference
between both groups which agrees with our study [4].
In a systematic review and meta-analysis on the efficacy
and safety of iodopovidone pleurodesis, Agarwal R. and
colleagues found that the success rate of iodopovidone
pleurodesis varied from 70 to 100 per cent in different
studies with the pooled success rate being 88.7 per cent
(95% CI, 84.1 to 92.1) by the random effects model. The
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thoracostomy or thoracoscopy was used for pleurodesis
(P = 0.13) [17].
In another systematic review that included 1,168
patients, Walker-Renard PB and colleagues found that the
complete success rate of talc was 93 per cent compared
with Corynebacterium parvum (76%), tetracycline (67%),
doxycycline (72%) and bleomycin (54%) [18].
Regarding the complications of our procedure, Chest
pain and fever were the most common adverse effects in
both groups. In our study, chest pain was recorded in 14
cases of group A and 9 cases of group B. Fever was the
second most common complication; 4 cases in each
group and anti-pyretic was given with close follow-up
and fever subside with no more side effects until removal
of the drain and discharge, with no statistically significant
difference between both group. There was no other
complication reported in our study. There was one
case of mortality recorded in group A with the cause
of death related to the primary tumor and not the
pleurodesis. No mortality detected in group B.
In Agarwal R. and colleagues study, all patients experi-
enced chest pain with median (IQR) Visual Analogue
Scale of 20 (10–30) mm and a range of 10–90 mm. Fever
occurred in nine patients (four in the iodopovidone group
and five in the talc group) and was self-limited. Two
patients (one in each group) developed empyema, which
was treated with antibiotics. None of the patients, in their
study, developed ARDS, visual loss or hypotension associ-
ated with administration of either agent [16].
Mohsen et al. agree with our results regarding post-
operative complications as chest pain was the most com-
mon complications (4 cases only with talc pleurodesis)
followed by fever (4 cases with talc pleurodesis, a single
case with Povidone-iodine pleurodesis) but without a
significant difference [4].
In their systematic review and meta-analysis, Agarwal
R. and colleagues found that there were no deaths, acute
respiratory distress syndrome (ARDS) or visual loss related
with iodopovidone pleurodesis. They found that the com-
plications reported of iodopovidone pleurodesis included
chest pain and systemic hypotension [17].
Concerns that Povidone-iodine might be associated with
visual loss were reported by Wagenfeld et al. in three cases
during VATS [19]. However, authors used an unusual large
amount of 200–500 ml of 10% Povidone-iodine [19]. They
also noted that the safe amount to be used is 20 ml of 10%
iodine, which is the amount that we have used in our
study. As an additional safety precaution, we administered
this dose in a diluted form (in normal saline).
The limitations of our study included the small sample
size and not measuring the pH of the pleural fluid which
can affect the success of pleurodesis as reported by some
authors [20].Conclusion
Based on the results of our study, Povidone-iodine was
shown to be an efficient pleurodesis agent and demon-
strated a good safety profile in treating malignant pleural
effusions with a good success rate and few minor compli-
cations. Therefore, it can be considered as a cost effective
alternative sclerosing agent for pleurodesis when talc is not
available or contraindicated.
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